0.2525

4.12% +0.01

After Hours: .2525

ENDRA Life Sciences Inc (NDRA)

Overview News Price History Discussions Forecast Stock Split

ENDRA Life Sciences Inc stock is currently priced at $0.2525, with a 24-hour trading volume of 11,072. It has seen a +4.12% increased in the last 24 hours and a -74.06% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.2441 pivot point. If it approaches the $0.2583 resistance level, significant changes may occur.

Previous Close:

$0.2425

Open:

$0.252

24h Volume:

11,072

Market Cap:

$2.79M

Revenue:

Net Income/Loss:

$-10.06M

P/E Ratio:

-0.0761

EPS:

-3.32

Net Cash Flow:

$-9.58M

1W Performance:

+2.23%

1M Performance:

-74.06%

6M Performance:

-73.97%

1Y Performance:

-84.51%

1D Range:

$0.2422

$0.2573

52W Range:

$0.221

$2.79

ENDRA Life Sciences Inc Stock (NDRA) Company Profile

Name

ENDRA Life Sciences Inc

Sector

Healthcare (1191)

Industry

Diagnostics & Research (66)

Phone

734 335 0468

Address

3600 Green Court, Suite 350, Ann Arbor, MI

Employee

Twitter

@endralifesci

Next Earnings Date

2024-05-13

Latest SEC Filings

NDRA's Discussions on Twitter

ENDRA Life Sciences Inc Stock (NDRA) Latest News

Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket

Benzinga

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

ENDRA Life Sciences Inc Stock (NDRA) Financials Data

ENDRA Life Sciences Inc (NDRA) Net Income 2024

NDRA net income (TTM) was -$10.06 million for the quarter ending December 31, 2023, a +23.66% increase year-over-year.

ENDRA Life Sciences Inc (NDRA) Cash Flow 2024

NDRA recorded a free cash flow (TTM) of -$9.58 million for the quarter ending December 31, 2023, a +26.13% increase year-over-year.

ENDRA Life Sciences Inc (NDRA) Earnings per Share 2024

NDRA earnings per share (TTM) was -$1.81 for the quarter ending December 31, 2023, a +60.82% growth year-over-year.

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.